If approved, the new autoinjector formulation would allow patients to administer furosemide at home reducing administration time from 5 hours to under 10 seconds.
If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 ...
A Prescription Drug User Fee Act target date of March 6, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application ...
CHICAGO -- The choice between furosemide and torsemide didn't matter for longer-term clinical outcomes of hospitalized heart failure patients, according to the comparative effectiveness trial ...
The FDA approved the first furosemide (Furoscix) formulation for subcutaneous self-administration by patients with congestive heart failure, scPharmaceuticals announced. The IV-equivalent formulation ...
SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the ...
A medication used to reduce fluid retention can also safely be used to prevent a dangerous lung condition that affects newborns, particularly those born premature, according to a new study. "There are ...
If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback